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ABSTRACT 
Background: In patients with anal squamous cell carcinoma (ASCC), lymph node positivity 
(LNP) indicates poor prognosis for survival and is central to radiotherapy planning. Over the 
past three decades, LNP proportions have increased, mainly reflecting enhanced detection 
with newer imaging modalities; a process known as nodal stage migration. If accompanied 
by constant T stage distributions, prognosis for both LN+ and LN- categories may improve; a 
paradox termed the Will Rogers phenomenon. The latter has not been systematically 
evaluated, in general, or for anal cancer. Here, we aim to systematically evaluate the impact 
of nodal stage migration on survival in ASCC and address a novel hypothesis that this 
phenomenon additionally results in reduced prognostic discrimination.   
Methods: We conducted a systematic review and meta-regression to quantify changes in 
LNP over time and the impact of this upon survival and prognostic discrimination. We 
searched Medline, Embase and the Cochrane Library  (until 11 October 2016) to identify 
studies in patients with ASCC, where chemo-radiotherapy or radiotherapy was the main 
treatment, that (i) reported LNP proportions; and (ii) evaluated the relationship of lymph node 
status with prognosis. To investigate scenarios where reduced prognostic discrimination 
might occur, we simulated varying true LNP proportions and true survival rates, and 
compared these with expected observed outcomes for varying levels of misclassification of 
true nodal state.  
Results: We included 62 datasets (10,569 patients). LNP proportions increased from a 
mean estimate of 15% (95% CIs: 10% to 20%) in 1980 to 37% (95% CIs: 34% to 41%) in 
2012 (p < 0.001). In 11 studies with prognostic data, increasing LNP was associated with 
improved overall survival in both LN+ and LN- categories, while the proportions with tumour 
stage T3/T4 remained constant. In 20 studies, across a range of LNP proportions from 15% 
to 40%, the hazard ratios for survival of LN+ versus LN- decreased significantly (p = 0.014) 
from 2.5 (95% CI: 1.8 to 3.3) to 1.3 (95% CI: 1.2 to 1.9), demonstrating the phenomenon of 
reduced prognostic discrimination. The simulated scenarios reproduced this phenomenon 
where the true proportions for LNP were either 20% or 25%, but not where the true 
proportions for LNP were 30% or greater, arguing that the true proportion of LNP might be 
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lower than that observed in modern clinical series, which generally observe LNP proportions 
greater than 30%. 
Interpretation: With nodal stage migration over time in anal cancer as an example, we 
describe a novel extension of the Will Rogers phenomenon, namely a form of 
misclassification that we have termed reduced prognostic discrimination. At a general level, 
the introduction of new staging technologies in oncology, which misclassify true disease 
stage, might spuriously inform management and ultimately have a risk of over-treatment.  
Funding: Bowel Disease Research Foundation (BDRF)  
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Research in context 
Evidence before this study 
In oncology, the Will Rogers phenomenon occurs when patients are re-classified from one 
tumour stage to another stage following the introduction of either a new diagnostic 
technology or a new staging system, and there is a consequent paradoxical improvement 
in survival rates of both stages. A seminal article illustrating this phenomenon as a source 
of misleading survival statistics was published in 1985. Our search in Medline (01 Jan 
1985 to 16 Oct 2016) identified only fourteen primary studies, which in the main, 
DGGUHVVHGFRQILUPDWLRQRI WKH:LOO5RJHUVSKHQRPHQRQLQ µEHIRUHDQGDIWHU¶DQDO\VHVRU
comparisons of different staging systems, across various cancer types. We found no study 
that systematically evaluated the phenomenon.  
Here, we extend the evaluation of the Will Rogers phenomenon with the example of anal 
cancer. For anal squamous cell carcinoma (ASCC), lymph node positivity (LNP) indicates 
poor prognosis for survival and is central to (chemo-)radiotherapy dose planning ± the 
main modality of initial treatment. There are six published phase III trials of chemo-
radiotherapy interventions in patients with ASCC. Secondary analyses from four of these 
show that, over the past three decades, LNP proportions have increased, mainly reflecting 
enhanced detection with newer imaging modalities. We hypothesise that this nodal stage 
migration (over time) is associated with improved prognosis in both LN+ and LN- 
categories, and if T stage at clinical presentation (the main prognostic factor for survival) 
otherwise remains constant, this fulfils criteria for the Will Rogers phenomenon. We 
additionally address a novel hypothesis that this occurrence results in reduced prognostic 
discrimination, as a form of misclassification, which in turn, might lead to over-treatment. 
Added value of this study 
Through systematic review, we used the strength of the literature of over ten thousand 
patients with anal cancer from 62 studies, and performed meta-regression demonstrating 
that, over the past three decades, there has been a near 7 percent increase in detection of 
lymph node positivity per 10 years. This nodal stage migration has occurred when the 
proportion of tumour stage T3/T4 remained relatively stable. By capturing this striking 
relationship between increased levels of LNP over time, we were able to infer that the 
factors driving the upward nodal stage migration (namely new imaging technologies) are 
concurrently: (i) improving prognosis for LN+ and LN- categories, thus fulfilling criteria for 
the Will Rogers phenomenon, while also (ii) resulting in a new observation, namely the 
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phenomenon of reduced prognostic discrimination. The simulated scenarios reproduced 
this phenomenon where the true proportions for LNP were either 20% or 25%, but not 
where the true proportions for LNP were 30% or greater, arguing that the true proportion 
of LNP might be lower than that observed in modern clinical series, which generally 
observe LNP proportions greater than 30%. 
Implications of all the available evidence 
The true performance characteristics (namely, sensitivity and specificity) of pre-treatment 
staging modalities are incompletely quantified for several cancer types in oncological 
practice because full histological confirmation of a carcinoma together with its lymphatic 
drainage field is generally absent. This case example of anal cancer (where pre-treatment 
staging is defined by imaging) illustrates the paradoxical possibility that the introduction of 
new and seemingly improved staging technologies in oncology might be associated with 
substantial misclassification of true stage; in turn, resulting in susceptibility to upward 
nodal stage migration, spuriously informing management, and ultimately a risk of over-
treatment. 
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INTRODUCTION 
Anal squamous cell carcinoma (ASCC) is a Human Papilloma Virus (HPV)-related 
malignancy1 2 whose incidence has increased substantially (2- to 4-fold) in both men and 
women over the past decades3, 4. Results from randomized trials, published in the 1990s, 
established combined chemo-radiotherapy (CRT) as the mainstay of initial treatment5-7; 
today about three-quarters of patients receive CRT as primary therapy8.  
Spread from the primary tumour is predominantly via lymphatic vessels to regional 
lymph node fields. Lymph node positivity (LNP) is an adverse prognostic factor, as reflected 
in the American Joint Committee on Cancer/International Union against Cancer 
(AJCC/UICC) staging system9. The 7th AJCC/UICC staging classification defined stages I 
and II by T1N0M0 and T2N0M0, respectively, while stage IIIA and IIIB are defined mainly by 
nodal positivity [T(1-3)N1M0; and T4N1M0, any TN2-3M0, respectively]9. Detection of LNP 
is central for planning radiotherapy doses and fields. Thus, many centres traditionally use 
regimens based on the ACT II trial10, with patients receiving radiotherapy doses of 50.4-54 
Gy to both the primary tumour and the involved nodal fields (broadly equivalent to stage III 
tumours), with reduced doses (30.6-36.0 Gy) to uninvolved nodal draining fields (stage I and 
II). 
Pre-treatment nodal staging is almost exclusively done by imaging. In the 1980s and 
1990s, staging was by clinical examination, supplemented with computerised tomography 
(CT). In the 2000, magnetic resonance (MR) was introduced2 and since 2010 Positron 
Emission Tomography (PET) has been recommended routinely or in selected patients to 
further enhance nodal staging11-13. Over the past three decades, LNP proportions have 
increased, probably driven by newer imaging technologies. For example, in trials performed 
in the 1990s, 17% of patients in RTOG 87-046 and 20% in ACT I5 were lymph node positive, 
rising to 27% in RTOG 98-11(1998 to 2005)14, and to 35% in ACT II10, which recruited from 
2001 to 2008, and where MR imaging was performed in approximately half of patients.  
The observation of increased nodal positivity over time is known as nodal stage 
migration, and if accompanied by constant T stage distributions, there is potential for 
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paradoxical improvements in survival for both LN+ and LN- patients. This is known as the 
Will Rogers phenomenon15. The latter is a form of reclassification and is well recognised in 
the oncology literature after the introduction of new imaging modalities in other cancers 
(detailed references in webappendix p1-2), but has not been systematically evaluated, in 
general or for anal cancer. Here, we aim to systematically evaluate the impact of nodal stage 
migration on survival in ASCC and address a novel hypothesis that this phenomenon 
additionally results in reduced prognostic discrimination, with the hallmarks of narrowing 
survival differences between LN+ and LN- categories. If true, this would represent a form of 
misclassification and a risk for potential over-treatment.  
 
METHODS  
Study design 
We conducted a systematic review and meta-regression to quantify changes in LNP over 
time and examined the associations between LNP and survival, and between LNP and 
prognostic discrimination. Here, we use the term prognostic discrimination as a clinical 
measure of a between category difference in survival rates, for example, at different time 
points or for different true LNP proportions. To determine whether nodal stage migration was 
accompanied by constant T stage distributions, in parallel, we quantified changes in T3/T4 
proportions over time. Because development of imaging technology and expansion of multi-
modality pre-treatment staging cannot be quantified directly, we used calendar time as a 
proxy measure. To better understand prognostic discrimination over time, we simulated 
hypothetical scenarios with varying levels of true LNP proportions; derived observed LNP 
proportions for varying test performance characteristics; and estimated the corresponding 
survival rates by observed nodal status. Throughout this paper, we use lymph node positivity 
(LNP) to indicate apparent clinical lymph node positivity determined by the study 
investigators at the time period for that study. For pragmatic reasons, we denoted LNP for 
involvement of any lymph nodal field draining the primary anal cancer (peri-rectal; iliac; 
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inguinal). The abbreviations LN+ and LN- were used to denote two strata of nodal status in 
prognostic modelling. 
 
Search strategy, inclusion criteria and data extraction 
We searched Medline, Embase and the Cochrane Library (until 11 October 2016) to identify 
potentially eligible randomised trials and observational studies in patients with ASCC. The 
search was limited to studies published in English from 01 Jan 1970 onwards, as RT or CRT 
was not used prior to 1970 (search details: webappendix p3-6. Reference lists of included 
papers were reviewed. 
Five criteria had to be met: (i) unselected patients with anal cancer where treatment 
was primarily RT and/or CRT (including studies that employed a boost dose or phase 2 dose 
with brachytherapy or interstitial radiotherapy and studies with <10% treated with primary 
surgery); (ii) histological diagnosis of ASCC (<10% of other histologies were accepted); (iii) 
treatment with curative intent (<10% palliative or M1 disease were accepted); (iv) nodal 
status work-up that included either clinical examination, non-invasive imaging, or imaging 
and fine needle aspiration cytology (FNAC); (v) TNM stage or nodal status was reported. We 
excluded studies with fewer than 50 subjects for the following reasons: (i) risk of 
disproportionate influence in the random-effects meta-regression models; and (ii) many 
focused on reporting new technologies in highly selected patient groups.  
The following data were extracted using a standardized, piloted form: study and 
participant characteristics; first and last years of enrolment, year of publication; T stage (7th 
AJCC)9; method of nodal staging; and proportion of patients with LNP.  
The primary outcome measure was overall survival (OS). For studies that reported 
survival data, we extracted 5-year OS rates for the total patient cohort, and by nodal status. 
Unadjusted and adjusted hazard ratios (HR) were extracted with standard errors (SEs) or 
95% confidence intervals (CIs); for the main analysis, maximally adjusted HRs were used. If 
not reported, we calculated HRs from actuarial rates as HR = lnP1/lnP2  (where P1 is the 
survival rate of the LN+ group and P2 the rate of the LN- group) and SEs as SE = 
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sqrt*(1/e1+1/e2) where e1 is the number of events in the LN+ group and e2 the number of 
events in the LN- group), or derived HRs based on data reconstructed from Kaplan-Meier 
survival curves for the whole study cohort and stratified by nodal status16.  
 
Assessment of risk of bias 
We developed a five-component assessment tool to gauge the risk of bias, based on cohort 
selection; treatment type (selection of patient sub-groups for treatment other than chemo-
radiotherapy); missing data; adjustment for potential confounding; and duration of follow-up. 
Not all criteria were relevant to each outcome. For example, follow-up was not assessed for 
studies of the proportion of patients with LNP. We classified risk of bias as high, moderate or 
low (detailed: webappendix p7). Studies where the risk of bias remained unclear were 
classified as high risk. 
 
Statistical Analysis 
For tables of study characteristics, summarised proportions across studies as mean 
proportions and ranges. For LNP proportions, we derived pooled estimates (and 95% 
confidence intervals, CIs) using the metaprop command in STATA. 
We calculated study-level proportions and 95% confidence intervals of LNP patients 
and combined T3/T4 stages using exact binomial confidence intervals. Proportions were 
entered into random-effects meta-regression models17 to assess their relationship with time. 
The majority of included studies were observational and there was an expected 
heterogeneity in the type and use of pre-treatment imaging for nodal staging over time for a 
given study. This heterogeneity was poorly reported. As an alternative, we sought to 
determine a time-poinWRIµDYHUDJH¶FOLQLFDOSUDFWLFHIRUWKHGHWHFWLRQRI/1RYHUWKHSHULRG
of a given study. We used median study year - that is year at which 50% of participants had 
been enrolled. We argued that for most treatment series, enrolment increases year on year. 
In the absence of parameters to estimate study-level medians, we used the 66th percentile 
year as an approximate based on in-house data (full justification: webappendix p8-10). In 
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sensitivity analyses, we repeated analyses using other timescales (first year of patient 
enrolment, last year of study enrolment, year of publication, and the 75th percentile year), 
and found similar patterns (webappendix 11).  
Similarly, we used meta-regression to assess temporal trends of 5-year OS 
estimates by nodal status. We expressed changes in prognostic discrimination as changes 
in differences in survival rates, and examined associations between changes in prognostic 
discrimination and proportions of LN+ versus LN- patients in meta-regression models.  
All meta-regression model were constructed using random-effects. We calculated 
prediction intervals and the between-VWXG\YDULDQFHDVĲ2. 
For further sensitivity analyses, we sought to assess the potential impact of between-
study heterogeneous characteristics on the main model and sequentially removed the 
following: studies with overlapping data (where data overlapped either in time or region 
without being duplicate data); studies that included patients with primary surgery, metastatic 
or palliative disease; and studies with histologies other than ASCC. We assessed for the 
influence of single studies on the summary estimates in a leave-one-out at a time approach. 
For prognostic studies, we addressed the effect of removing cohorts with fewer than 90% of 
patients treated with CRT, cohorts reporting univariate HRs only, and HRs estimated from 
actuarial rates and reconstructed data. Publication bias was assessed using funnel plots18. 
 
Simulations  
In simulated studies, we explored mechanisms that may explain the effect of misclassified 
true node positivity on observed prognostic discrimination. We first created hypothetical 
single population of one million persons with varying levels of true LNP (20%, 25%, 30% and 
35%). In a second step, we assumed that 5-year OS depends on true nodal status with 5-
year OS set at 85% for true LN- and at 35% for true LN+ status (webappendix p12-15). With 
these assumptions, we simulated deaths assuming a Bernoulli distribution. In a third step, 
we derived a range of observed LNP proportions by varying the performance characteristics 
(sensitivity and specificity) of a hypothetical pre-treatment imaging test and then calculated 
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5-year OS according to observed nodal status. Finally, we regressed the average 5-year OS 
by the mean of observed LN status separately for positive and negative LN status. The 
mean LN status was obtained over different combinations of sensitivity and specificity. To 
define plausible ranges of sensitivity and specificity, we explored the literature for 
performance characteristics of pre-treatment imaging tests commonly used for anal cancer 
but found a limited number of studies; that meta-analyses were inconsistent 19, 20; and 
concluded study quality was poor, mainly due to lack of a referent standard and high 
susceptibility to verification bias. Thus, we used a wide range of plausible sensitivities (5% 
increments from 40% to 95%) and specificities (1% increments from 68% to 97%), and 
varied both independently. Finally, to gauge which levels of true LNP were compatible with 
the observations from our systematic review, we plotted the mean 5-year OS by the mean of 
observed LNP.    
All analyses were performed in Stata (version 14, Stata Corp., TX, USA) or in R, 
using R-3.2.2 (R Core Team, Austria, 2015).  
 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all of the 
data and the final responsibility to submit for publication. 
 
RESULTS 
Included studies 
The process of identifying eligible studies is shown in Figure 1. We included 62 studies that 
met all five eligibility criteria. Excluded studies and reasons for exclusion are detailed in 
webappendix p16-24.  Forty-five studies contributed to analyses of 5-year OS; 11 studies to 
5-year OS stratified by nodal status; and 20 studies contributed HRs comparing 5-year OS in 
LN+ and LN- patients.  
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Study characteristics 
The 62 studies included 10,569 patients, and were published between 1984 and 2016; the 
year of last study ranged from 1979 to 2014. The pooled estimated LNP proportion at 
presentation was 28.8% (95% CIs: 26.5% to 31.1%) (webappendix p25-28). Data were 
mainly from institution-level treatment series but also included three randomised trials;5, 6, 10 
one national database;21 and one cancer registry22. Ten pairs and one triplet of studies 
reported overlapping data (webappendix p29-30). The characteristics of the 45 studies 
(6,302 patients) and 11 studies (1,332 patients) included in the analysis of 5-year OS, and 5-
year OS by nodal status, respectively, are detailed in webappendix p31-34. Median follow-up 
periods ranged from 1.2 to 8.6 years in the former group of studies, and from 3.4 to 8.2 
years in the latter group. Pooled estimated LNP proportions were similar to that for the 
complete dataset of 62 studies:  namely, 29.0% (95% CIs: 26.1% to 31.9%) and 27.0% (95% 
CIs: 21.6% to 32.3%). Estimates of 5-year OS were derived from reconstructed data from 
Kaplan-Meier curves in 17 and 3 studies, respectively. In most studies, CRT was either the 
sole or dominant treatment modality.  
The majority of the 20 studies (4,048 patients) contributing HRs of 5-year OS 
comparing LN+ and LN- patients were published after 2000 (Table 1). Data were from one 
randomised trial5; one cancer registry22; and institution-level treatment series23-40. Median 
follow-up periods ranged from 1.3 to 8.6 years. Again, the pooled estimated LNP proportion 
was similar to that for the complete dataset of 62 studies: 27.7% (95% CIs: 24.2% to 31.2%). 
 
Assessment of Study Methodological Quality 
We assessed the methodological quality (webappendix p35) of all 62 studies reporting LNP 
proportions on two attributes: patient selection and missing data. The majority of studies 
were low risk. For the studies reporting 5-year OS for whole cohorts (45 studies) and by 
nodal status (11 studies), we assessed four attributes: cohort selection; treatment type; 
missing data; and follow-up. Many studies had moderate to high risk of bias of treatment 
type (due largely to the selection to use brachytherapy or interstitial therapy for radiotherapy 
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boosts); missing data (largely due to unclear reporting); and inadequate follow-up time 
(median follow-up < 5 years). For the 20 studies reporting HR, we assessed five attributes: 
cohort selection; treatment type; missing data; confounding; and follow-up. Again, many 
studies exhibited moderate to high risk of bias secondary to treatment type; missing data; 
and inadequate follow-up; and also confounding. Of the 20 studies, nine did not include 
adjustments. Where there were adjustments: all eleven studies adjusted for either T status, 
T size or N stage; four adjusted for histology; three adjusted for performance status; six and 
eight studies adjusted for age and gender, respectively.  
 
Trends in lymph node positivity over time  
In meta-regression analyses, there was a clear increase in observed LNP over time 
(p<0.001) (Figure 2A). The proportion of apparent LN+ patients increased by 6.8% (95% 
CIs: 4.4% to 9.3%) per decade; the predicted mean LNP proportion was 15% (95% CIs: 10% 
to 20%) in 1980 increasing to 37% (95% CIs: 34% to 41%) in 2012. In contrast, the 
proportion with stage T3/4 disease remained essentially constant over time (Figure 2B). 
Thus, we found evidence for nodal stage migration without corresponding change in T stage 
at presentation. There was little evidence for associations between LNP and other variables 
including study type, country, mean age, percent females, HIV status and tumour location 
(webappendix p36). 
 
Survival by nodal status 
We next examined whether nodal stage migration was associated with improved prognosis 
in LN+ and LN- patients (i.e., the :LOO5RJHUV¶phenomenon). Based on 11 studies, the meta-
regression analysis showed that there were indeed improvements in 5-year OS in both LN+ 
and LN- patients with increasing observed LNP (Figure 3). For example, at 20% proportion 
of LNP, survival was 47% (95% CIs: 33% to 60%) in LN+ and 70% (95% CIs: 64% to 77%) 
in LN- patients, but 63% (95% CIs: 50% to 76%) and 78% (95% CIs: 71% to 85%), 
respectively, at a LNP of 35%.  
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For the analysis across 45 studies, consistent with the literature8, 5-year OS rates 
increased from a mean estimate of 64% (95% CIs: 58% to 71%) in 1980 to 75% (95% CIs: 
70% to 79%) in 2010 (p = 0.046]. Among ten of the 11 studies (with survival data by nodal 
status) and where full cohort survival was reported or derived, the 5-year OS rates increased 
over time in a similar manner to the model of 45 studies [64% (95% CIs: 51% to 76%) in 
1980 to 72% (95% CIs: 63% to 81%) in 2010], though not statistically significant 
(webappendix p37). 
 
Prognostic discrimination 
For the 11 studies that reported paired OS rates, the prognostic discrimination between LN+ 
and LN- patients declined with increasing observed LNP. At a LNP proportion of 20%, the 
difference between mean predicted 5-year OS rates for LN- minus LN+ was 23% (70% 
minus 47%); at a LNP proportion of 35%, the difference was only 15% (78% minus 63%) 
(Figure 3). We explored this further in a meta-regression of the 20 studies providing HRs for 
OS by nodal status. Across a range of LNP proportions from 15% to 40%, the HRs of LN+ 
versus LN- decreased significantly (p = 0.014) from 2.5 (95% CI: 1.8 to 3.3) to 1.3 (95% CI: 
1.2 to 1.9) (Figure 4). Similar patterns were noted with time as the x-axis (p = 0.052) 
(webappendix p38).  
We investigated scenarios where reduced prognostic discrimination might occur 
using simulations and reproduced the findings from the meta-regressions of decreasing 
between nodal status survival differences within increasing true proportions of LNP. 
However, this phenomenon was limited to the scenarios of true LN+ proportions 20% and 
25% (Figure 5), and absent in the scenarios of higher true proportions (30% and 35%). The 
patterns, and reductions in prognostic discrimination, for example, from 25.1 to 15.7 for true 
LNP 20% in the simulated scenarios mirrored those from the literature shown in Figure 3. 
Table 2 shows the summary outputs from the simulations. For example, in the 
simulation of true LNP of 20%, observed node positivity of 20% arises where there is 
moderate sensitivity (mean: 63.5%) and high specificity (mean: 90.7%); however, a 
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moderate increase in sensitivity (mean: 68.5%) but without a proportionate maintenance of 
high specificity (decreased to mean: 73.3%) gives rise to a misclassification of observed 
node positivity of 35% (as reported in many contemporary studies).  In the simulation of true 
node positivity of 35%, observed node positivity of 35% arise where there is moderate 
sensitivity (mean 66.5%) and high specificity (mean: 81.9%); a plausible scenario with 
modern imaging, but in the latter simulation, there is no reduced prognostic discrimination. 
The presence of reduced prognostic discrimination in the scenarios of true LNP of 20% and 
25% argue that the true proportion of LNP might be lower than that observed in modern 
series (typically 35%). 
 
Sensitivity analyses 
For the meta-regression of LNP proportions over time (62 studies), similar results were 
found after excluding: studies with overlapping data; studies with patients treated with 
primary surgery; studies with patients with M1 disease; and studies that only reported 
inguinal node detection (webappendix p39). On the modelling of hazard ratios for overall 
survival by nodal status (20 studies), we repeated the meta-analyses stratified by study 
characteristics and designs, and tested for interactions, and found none (webappendix p40). 
We found similar summary risk estimates obtained from: studies where over 90% of patients 
received CRT versus those where less than 90% of patients received CRT; unadjusted 
versus adjusted HRs, both for all studies and where same studies reported both; or how HRs 
were derived (directly from Cox model, survival rates, or reconstructed data).   
 We noted that some studies, for example, that of Salmon et al.23 with a last year of 
patient enrolment at 1979 might be an outlier. We repeated the meta-regressions of LNP 
versus median study year, excluding one study at a time, and found similar results 
(webappendix p41). 
 
Publication Bias 
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A funnel plot of the twenty studies with HR of OS stratified by nodal status was constructed 
to assess for publication bias (webappendix p42). There was no clear evidence of 
asymmetry. 
 
DISCUSSION 
Summary of main findings 
Among patients with anal cancer, our meta-regression demonstrated that, over the past 
three decades, there has been a near 7 percent increase in detection of lymph node 
positivity per 10 years. This nodal stage migration has occurred when the proportion of stage 
T3/T4 disease remained relatively stable, and is likely to be driven by increased sensitivities 
of new imaging technologies. The increase in LNP proportions was associated with 
improved 5-year OS rates in both LN+ and LN- groups of patients, thus fulfilling criteria for 
WKH:LOO5RJHUV¶SKHQRPHQRQ:HREVHUYHGDQHZSKHQRPHQRQDUHGXFWLRQLQSURJQRVWLF
discrimination, with a reduction in study-level hazard ratios for nodal positivity over time. This 
is a misclassification and represents an extension of the process of stage migration. The 
simulated models replicated the reduced prognostic discrimination, but only for true LNP 
proportions of 20% and 25%, arguing that the true proportion of LNP might be lower than 
that observed in modern clinical series, which generally observe LNP proportions greater 
than 30%. At a general level, the introduction of new pre-treatment staging technologies and 
biomarker in oncology might be associated with substantial misclassification of true stage; in 
turn, spuriously informing management with risk of over-treatment. 
 
Context of other literature 
To our knowledge, this is the first large-scale review with meta-regression, in patients with 
anal cancer, of the prevalence of lymph node positivity; temporal changes in proportions with 
LNP; and the impact of these on prognosis. Lymph node positivity is considered a major 
adverse prognostic factor in anal cancer, as reflected in the AJCC/UICC staging system 9 
and in recent prognostic studies in trial patients 41. Its importance in treatment algorithms is 
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reflected in current guidelines in North America 42 and Europe 13. Researchers have explored 
opportunities to refine the definitions of pre-treatment nodal status ± for example with 
sentinel node biopsy 43, 44. However, with increasing reliance on PET-CT for the detection of 
lymph node positivity 42, sentinel node biopsy has not gained widespread clinical use in 
patients with anal cancer. As initial radiotherapy treatment in patients with anal cancer 
moves away from conventional to a multi-field (modulated) technique 42, identification of 
nodal involvement will remain important. 
The Will Rogers phenomenon is well-known in the cancer literature. This typically 
occurs following the introduction of new diagnostic or staging tests, which generally has 
increased sensitivity 15, 45, 46, thus allowing the detection of metastatic tumour deposits that 
were previously occult. The phenomenon may also occur after the introduction of new 
staging criteria47. This results in the reclassification of more patients into a higher disease 
stage or prognostic score, apparent stage-specific improvements in prognosis, but without 
altering survival in the individual patient ± hence, the paradox. As a secondary finding, we 
showed improvement in overall survival with time, as noted in a UK population-based study.8 
In their classical paper in 1985, Feinstein et al. 15  LQGLFDWHGWKDW³WKHWRWDOVXUYLYDOUDWHLQWKH
FRKRUWLVXQDIIHFWHG´ZKLFK LV WUXHRYHUDVKRUW WLPHVSDQ%XW LQ WKHSUHVHQWVWXG\DQG
indeed in the lung cancer example in the classical paper 15), over a longer duration, there 
may be gradual improvement in survival due to period effects, such as treatment 
centralisation, improvements in medical management and in management of treatment-
related morbidities.   
To date, the implication of the Will RoJHUV¶SKHQRPHQRQKDVEHHQPDLQO\WRFDXWLRQ
researchers of the limits of using historical control groups for comparison on outcomes. 
Here, we demonstrate the additional phenomenon of reduced prognostic discrimination. This 
has wider clinical implications: (i) risk of over-diagnosis and over-reliance on nodal stage as 
a prognostic marker to guide treatment; and (ii) risk of under-powering a trial, if for example, 
a new diagnostic modality is introduced into a trial in addition to a new intervention.  
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It is important to note that this study did not aim to establish that newer imaging 
modalities were the cause of the observed :LOO 5RJHUV¶ SKHQRPHQRQ EXW UDWKHU WR
determine the impact of nodal stage migration on survival. Indeed, influences other than 
improved imaging technologies may have contributed, such as treatment centralisation and 
the development of anal cancer multidisciplinary meetings. Additionally, there might be 
biological explanations. For example, in oropharyngeal carcinoma, the proportion that is 
HPV-positive has increased with time, and in turn (compared with non-HPV-related), these 
HPV-positive tumours are associated with higher lymph nodal positivity; yet are more radio-
sensitive, and hence, have a better oncological outcome48, 49. This mechanism might operate 
for ASCC, though less likely to substantially influence survival as near 95% of ASCCs are 
HPV positive1.  
 
Limitations and strengths 
Our study has limitations. First, meta-analyses of observational studies are prone to the 
biases and confounding factors that are inherent in the original studies50. To address this, we 
assessed the methodological quality of key study-level domains, and found that many 
studies used in the prognostic analyses were at moderate to high-risk for inadequate 
adjustment for confounding. We compared, where possible, summary estimates for studies 
that reported univariate and multivariable analyses, and found no material differences. 
Second, we assumed that the period effect is, in the main, driven by introduction of new 
imaging technologies. However, data on imaging were difficult to extract from studies as 
these frequently were not well-described and often included a heterogeneity of imaging 
modalities. As a pragmatic alternative, we took study-level median study year as a surrogate 
of the representative imaging modality used in a given study. Third, reporting of survival data 
was frequently incomplete or missing. To counter this, we reconstructed data from Kaplan-
Meier curves, based on a validated algorithm 16. We made assumptions to derive hazard 
ratios in studies that reported survival rates only ± to mitigate against this by undertaking 
meta-analyses with and without these studies, and found no material differences. We still 
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failed to capture all reported survival stratified by nodal status, such that there might be a 
differential outcome reporting bias. Fourth, there was considerable unexplained between-
study heterogeneity in most of meta-regression models. 
Additionally, there are temporal changes in treatment-related factors that are sources 
of potential residual confounding. First, there is known wide variation in radiotherapy 
practice, and in particular, whether prophylactic inguinal nodal radiation is used. Different 
treatment modalities might influence loco-regional failure rates, but data from the six 
published randomized trials in this field suggest that the latter does not influence survival 
(webappendix p43). Second, technical refinements in salvage surgery might account for 
some increase in long-term disease-free states, but primary loco-regional failure rates have 
reduced substantially (from 35% in the 1990s5 to approximately 20% by 2010) such that 
salvage surgery is now less often required. Furthermore, among patients with local relapses, 
the proportions that proceed to salvage surgery has decreased from over 70% in historic 
series25, 51 in the 1990s to only 23% in the ACT II trial, from the mid-2000s.52 Third, 
enhanced detection and treatment of distant metastases might improve survival, but 
metastatic disease is relatively uncommon in anal cancer and most phase II chemotherapy 
trials show no significant benefit in this setting (reviewed elsewhere2). Finally, advances in 
the management of HIV-patients may account for some survival improvements. But, while 
HIV-positivity is a risk factor for incident ASCC, with the exception of five highly-selected 
US/German/French institute series, HIV positive cases generally account for less than 11% 
of anal cancers (webappendix p25-28) and improvements in HIV-related treatment is unlikely 
to substantially alter survival rates in the totality of anal cancer patients. 
 The study has a number of strengths. First, we exploited the power of meta-analysing 
many studies, with moderately large numbers of patients with anal cancer (an uncommon 
cancer), including data published over three GHFDGHV7KLV WHPSRUDO µOLEUDU\¶RIGDWDZRXOG
not be very common for a single institute series. Second, we harnessed the heterogeneity of 
the meta-analysis of LNP proportion over time to demonstrate a clear temporal relationship 
and speculate that one explanation is through the different modalities of imaging. We 
20 
 
recognise that, in modern clinical practice, imaging modalities are commonly used in 
combination ± our approach may have simplified this, but was pragmatic. Third, to test the 
clinical impact of the increasing rate of LNP with time, we additionally explored (through 
meta-analyses) the relationships with LNP proportion and survival, and through this, for the 
first time, we described the reduction of prognostic discrimination, as an extension of the 
process of stage migration.  
 
Clinical implications and future research 
Identification of lymph node positivity at the pre-treatment stage is central to chemo-
radiotherapy planning. Modern clinical practice in many European centres is with IMRT 
(Intensity Modulated RadioTherapy), but the principles remain - reduced prophylactic 
inguinal irradiation in node negative patients; and a gross tumour dose of 50.4 ± 54.0Gy in 
25-28 fractions to areas of primary tumour and lymph nodal involvement. The latter is 
associated with greater early and late treatment-related morbidity, compared with the former. 
With increasing LNP proportions, the proportion of patients requiring higher RT doses and 
volumes increases and may translate into higher treatment-related morbidity, but with 
continually changing management, this hypothesis is near impossible to test. 
 The concept of stratified treatment in anal cancer is being explored with the current 
availability of treatment intensification using IMRT ± for example, in the UK PLATO trial53. 
This approach aims to provide dose intensification to those patients thought to be at high-
risk of disease relapse (including node-positivity) and provide more conservative 
radiotherapy doses to those at low-risk, to reduce toxicity profiles. Our study highlights the 
importance of continually evaluating the modalities that classify nodal status in patients with 
anal cancer, to inform future trials of stratified treatment approaches.  
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Table 1: Twenty studies included in analysis of prognostic influence of nodal status (all had hazard ratios for overall survival)  
 
Author Study years Study design n Node 
positiv
e (n, 
(%)) 
Treatment N (%) 
treated 
with 
CRT 
Median 
follow up 
(range) 
Confounders 
adjusted for 
5-yr 
actuarial 
rates (LN- 
vs LN+) 
(95% CI) 
Hazard Ratio 
(95% CI) 
Estimated 
from 
actuarial 
results or 
reported 
HR  
Actuarial OS if 
used reported in 
paper or obtained 
from KM curve 
reconstruction 
Salmon ± 1984 
France23 
1968 - 1979 Institute 
treatment series 
183 23 
(12.6) 
RT 0 Not stated No adjustments  3.23  
(1.91 ± 5.47) 
Estimated Reconstructed  
Svensson  - 1992, 
Sweden24 
1985 - 1990 Institute 
treatment series 
82 12 
(14.6) 
RT +/- Bleomycin 43  
(57) 
2.7  
(0.08±
7.09) 
Age, T stage, nodal 
status, gender, tumour 
site, histology 
 1.87  
(0.62 -5.61) 
HR - MVA Not available 
Arnott ± 1996 UK5 
Gynne-Jones ± 
2013 UK41 
1987 - 1994 RCT 275 
CRT 
only 
60 
(21.8) 
RT vs RT+5FU+MMC 
(prognostic analysis only 
uses CRT arm) 
275 
(100) 
3.5  
(IQR: 
 2.3 ± 5.2) 
Gender, nodal status, 
age, White blood cell 
count, Haemoglobin 
 1.74  
(1.17 ± 2.58) 
HR - MVA Not available 
Grabenbauer ± 
2005 Germany26 
1985 ± 2001 Institute 
treatment series 
101 27 
(26.7) 
RT + 5FU + MMC 101 
(100) 
7.5  
(1 ± 16) 
No adjustments  1.74  
(0.81 ± 3.76) 
Estimated Reported  
Nilsson ± 2005, 
Sweden25 
1985 - 2000 Institute 
treatment series 
308 81 
(26.3) 
RT +/- 
bleomycin/Carboplatin/Cis 
156  
(51) 
5.5  
(1 ± 16) 
Gender, age, tumour 
site, histology, tumour 
size, nodal status 
 1.50  
(0.95 ± 2.37) 
HR - MVA  
Das ± 2007 USA27 1992 ± 2004 Institute 
treatment series 
167 65 
(38.9) 
RT + 5FU + Cis/MMC 167 
(100) 
3.5  
(0.2± 12.2) 
nodal status, HIV 
status 
 1.54  
(1.18 ± 2.00) 
HR - MVA Not available 
Widder ± 2008 
Austria28 
1990 ± 2002 Institute 
treatment series 
129 31 
(24.0) 
RT + 5FU + MMC 95  
(74) 
3.9 T stage, Nodal status, 
age, gender, overall 
treatment time, split 
course, total radiation 
dose, RT and 
chemotherapy 
 2.09  
(1.21 ± 3.62) 
HR - MVA  
Fraunholz ± 2011 
Germany29 
1997 - 2008 Institute 
treatment series 
70 19 
(27.1) 
RT + 5FU + MMC 80  
(100) 
4.25  
(0.3± 19.6) 
No adjustments  2.83  
(1.10 ± 7.27) 
Estimated Reported  
Wolfff ± 2011 
Germany30 
1992 ± 2004 Institute 
treatment series 
72 22 
(30.6) 
RT + 5FU + MMC 65 
(90.3) 
7.7 
(0.8± 17.2) 
No adjustments  3.02  
(1.37 ± 6.70) 
Estimated Reported 
De Foe ± 2012 
USA31 
2003 - 2009 Institute 
treatment series 
78 25 
(32.1) 
 77 
(98.7) 
1.3  
(0 ± 6) 
No adjustments  0.76  
(0.28 ± 2.10) 
Estimated Reconstructed  
Chuong ± 2013 
USA33 
2000 - 2011 Institute 
treatment series 
89 29 
(32.6) 
RT + 5FU + MMC 89 (100) 2.2  
(0.3± 11.1) 
Treatment, age, 
gender, T stage, nodal 
status, RT break 
 2.02  
(0.40 ± 10.31) 
HR - MVA Not available 
Eng ± 2013 USA35 1989 - 2009 Institute 
treatment series 
201 76 
(37.8) 
RT + 5FU/capcitabine + 
Cis 
100 8.6 Not stated  1.15  
(0.88 ± 1.51) 
HR - UVA Not available 
Fakhrian ± 2013 
Germany36 
1988 - 2011 Institute 
treatment series 
138 76 
(29.0) 
RT + 5FU + MMC 116  
(84) 
8.6 T Stage, UICC clinical 
stage, histology, 
ECOG performance 
status, radiotherapy 
technique, gender 
 1.28  
(0.62 ± 2.64) 
HR - MVA  
Kim ± 2013 
Korea34 
1979 - 2008 Institute 
treatment series 
50 18 
(36.0) 
RT + 5FU + MMC 49  
(98) 
5  
(0.7± 16.8) 
Gender, performance 
status, nodal status, 
clinical complete 
 2.80  
(0.60 ± 12.07) 
HR - MVA Not available 
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remission.  
Lestrade ± 2013 
Italy32 
1993 - 2009 Institute 
treatment series 
76 14 
(18.4) 
RT + 5FU + MMC 39  
(51) 
5  
(0.6± 17.0) 
No adjustments 75.9% 
(65.2 ± 
86.6) vs 
75.7 (53.2 
± 98.2)% 
1.01  
(0.31 ± 3.28) 
Estimated Reported 
Toh ± 2013 UK37 2004 - 2011 Institute 
treatment series 
92 30 
(32.6) 
CRT (no further details 
provided) 
92  
(100) 
2.7  
(1.3 ± 5.0) 
Gender, 
neutrophil:lymphocyte 
ratio 
 1.30  
(0.39 ± 4.35) 
HR - MVA Not available 
De Bari ± 2014 
Switzerland39 
2010 ± 2012 Institute 
treatment series 
100 29 
(29.0) 
RT + 5FU + Cis 58  
(58) 
3.4  
(0.1± 19.8) 
No adjustments 62% (50.7 
± 73.3) vs 
59% (41.4 
± 76.9) 
1.10  
(0.56 ± 2.18) 
Estimated Reported 
Leon ± 2014 
Sweden, Norway, 
Denmark22 
2000 - 2007 Registry based 
study 
1266 402 
(31.8) 
RT + 5FU +/ MMC/5FU + 
Cis 
669  
(53) 
4.2  
(1.0 ± 9.1) 
Age, gender, TNM 
stage, performance 
status, non-protocol 
treatment 
 1.58  
(1.25 ± 2.18) 
HR - MVA Not available 
Yeung ± 2014 
USA38 
2000 - 2010 Institute 
treatment series 
169 44 
(26.0) 
RT + 5FU + MMC 169 
(100) 
3.3  smoker, ECOG 
performance status, 
squamous cell 
histology, N status, T 
stage, MMC2 chemo  
 3.39  
(1.54 ± 7.49) 
HR - MVA Not available 
Oblak ± 2016 
Slovenia40 
2003 - 2013 Institute 
treatment series 
100 35 
(35.0) 
RT + 5FU + MMC 100 
(100) 
4.3  
(0.1± 10.8) 
No adjustments  2.06  
(1.09 ± 3.90) 
Estimated Reported 
  
      
     
  
Total 3740     
     
  
Pooled 
proportion 
estimate  
(95% CIs)* 
 27.7 
(24.2 ± 31.2) 
   
     
             
HR = Hazard Ratio.  CRT = chemoradiotherapy. RT = radiotherapy. 5FU = 5 ± fluorouracil. MMC = Mitomycin C. Cis = Cisplatin 
UVA = Univariate. MVA = Multivariable. KM = Kaplan-Meier. 
IQR: inter-quartile range. CI: confidence interval. 
*derived using the metaprop command in Stata 
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Table 2 The effect of misclassified true lymph node positivity (LNP) on observed prognostic discrimination 
 
 
Lymph node positivity (LNP) classification 
  
True LNP 
20% 
True LNP  
25% 
True LNP 
 30% 
True LNP 
 35% 
 
Mean observed LNP  20% 35% 20% 35% 20% 35% 20% 35% 
Mean (range) sensitivities for mean observed LNP* % 
63.5  
(40-90) 
68.5  
(45-90) 
55.8  
(40-75) 
67.0  
(40-90) 
49.3  
(40-60) 
67.6  
(40-90) 
45.0  
(40-50) 
66.5  
(40-90) 
Mean (range) specificities for mean observed LNP* % 
90.7  
(84-97) 
73.3  
(68-79) 
91.9  
(92-97) 
75.6  
(68-84) 
92.6  
(88-97) 
78.9  
(68-89) 
93.3  
(90-97) 
81.8  
(68-96) 
 
 
5-year survival rates % 
Observed LN negative mean survival rate  
&,V 
79.8 
(79.6-80.1) 
80.7 
(80.3-81.0) 
77.9 
(77.4-78.3) 
79.5 
(79.1-79.8) 
75.4 
(74.9-76.0) 
78.0 
(77.7-78.3) 
72.5 
(71.8-73.2) 
76.1 
(75.8-76.5) 
Observed LN positive mean survival rate  
(95% CIs)  
54.8 
(53.9²55.6) 
64.9 
(64.0-65.8) 
51.0 
(50.0-52.1) 
59.4 
(58.6-60.2) 
48.5 
(47.3-49.7) 
54.9 
(54.1-55.6) 
47.0 
(45.6-48.3) 
51.4 
(50.8-52.1) 
 
Mean survival (%) difference (LN- versus LN+) at 
mean observed LNP of 20% 
25.1 
(23.9-26.2)  
26.8 
(25.4-28.3)  
26.9 
(25.1-28.7)  
25.6 
(23.6-27.6)  
Mean survival (%) difference (LN- versus LN+) at 
mean observed LNP of 35%  
15.7 
(14.5-16.9)  
20.0 
(18.9-21.2)  
23.1 
(22.0-24.1)  
24.7 
(23.7-25.7) 
Reduction (%) in prognostic discrimination at mean 
observed LNP 20% versus 35% 
9.3 
(9.2-9.4) 
6.8 
(6.5-7.1) 
3.8 
(3.1-4.5) 
0.9 
(-0.1-1.9) 
* Based on distributions of sensitivities and specificities for observed LNPs between 19% and 21%, and between 34% and 36%, respectively, for assigned mean observed LNP 
20% and 35%. 
Based on regression models for the assigned mean observed LNP 20% and 35%. 
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FIGURE LEGENDS 
 
Figure 1 1 Flow diagram of articles identified and screened for eligibility 
a
 23 datasets contributed from K-M reconstructions 
b
 5 datasets contributed from K-M reconstructions 
c
 2 datasets contributed from K-M reconstructions 
 
Figure 2 A. Meta-regression of reported lymph node positivity (LNP) versus median study 
year. Circles represent individual studies (62 studies). B. Meta-regression of proportion of 
T3/T4 tumours versus median study year. Circles represent individual studies (61 studies). 
For A and B, the sizes of the circles are proportional to study sample sizes (ranging from 50 
to 1266 participants). Dashed lines are 95% confidence intervals (CI) and prediction intervals 
(PI). 
 
Figure 3 Meta-regression plots of 5-year overall survival against LNP stratified by nodal 
status. The vertical dashed grey lines indicate paired LN+ and LN- categories per study. The 
vertical double arrowed lines are mean differences in survival at 20% and 35% LNP. The 
values in parentheses are modelled 5-year overall survival rates at the respective LNP. The 
sizes of the circles are proportional to the sample sizes by nodal status.  
 
Figure 4 Meta-regressions of LNP against the hazard ratio of the effect of nodal status on 
overall survival. Dashed lines are 95% confidence intervals (CI) (red) and prediction intervals 
(PI) (yellow). Circles represent individual studies (20 studies); the sizes of the circles are 
proportional to study sample sizes (ranging from 50 to 1266 participants). Note: the y-axis is 
log scale.  
 
Figure 5 We constructed simulated scenarios with varying true LNP proportions (20%, 25%, 
30% and 35%). The true survival rates were fixed at 85% and 35%, respectively. Survival 
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rates for the observed LN- versus LN+ states are plotted. The prognostic discrimination at 
20% and 35% observed node positive proportions for each scenario are summarised in 
Table 2. Shaded areas are 95% confidence intervals (derived from the standard error of the 
forecast, and thus, are equivalent to predictive intervals in Figure 3); continuous bold lines 
are mean survivals.  
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